Zimmer Biomet Holdings (NYSE:ZBH) reported Q2 EPS of $1.82, $0.18 better than the analyst estimate of $1.64. Revenue for the quarter came in at $1.78 billion versus the consensus estimate of $1.72 billion.
GUIDANCE:
Zimmer Biomet Holdings sees FY2022 EPS of $6.70-$6.90, versus prior of $6.65-$6.85 and the consensus of $6.72. Sees revenue -1% to +1%.